What AskBio Presented on the GenePHIT Heart-Failure Gene-Therapy Trial at ESC 2026

AskBio used ESC Congress 2026 in Munich to present baseline characteristics from GenePHIT, its completed-enrollment Phase 2 trial of investigational umiposgene parvec, also known as AB-1002. The central update was the study’s scale and design—not a positive efficacy result. AskBio said the first randomized efficacy and safety outcomes are expected in the first half of 2027. 15

The key update: 173 participants, 64 sites, 12 countries

GenePHIT randomized 173 participants at 64 sites in 12 countries, making it one of the larger heart-failure gene-therapy studies reported to date. The enrolled population consisted of medically stable adults with non-ischemic cardiomyopathy, a left ventricular ejection fraction of 15% to 35%, and persistent New York Heart Association (NYHA) class III symptoms despite guideline-directed treatment. 15

That focus is important: the trial is studying patients with substantial symptomatic heart failure and reduced pumping function, rather than a broad population with any form of heart failure.

How the GenePHIT trial is designed

GenePHIT is an adaptive, multicenter, randomized, double-blind, placebo-controlled Phase 2 study. Participants were assigned in three groups: two AB-1002 dose levels or placebo. The treatment was delivered as a single antegrade intracoronary infusion, a catheter-based approach intended to deliver the gene therapy to cardiac muscle. 2

The primary efficacy assessment occurs at 52 weeks and uses a hierarchical composite, or modified win-ratio, approach. Rather than relying on one functional measurement, the framework gives priority to clinically meaningful outcomes and then evaluates measures such as heart-failure functional status and cardiac performance. Safety and tolerability are assessed alongside efficacy. 4

This design allows the study to test two related questions: whether a one-time dose can produce a meaningful difference compared with placebo, and whether the treatment can do so without unacceptable safety risks.

What AB-1002 is intended to do

AB-1002 is a cardiotropic adeno-associated virus gene therapy that delivers a gene encoding constitutively active inhibitor-1, or I-1c, to cardiomyocytes. The strategy targets a regulatory pathway involved in calcium cycling inside heart-muscle cells. 15

In simplified terms, I-1c is intended to inhibit protein phosphatase-1. That may reduce phospholamban-mediated inhibition of SERCA2a, a protein involved in moving calcium back into the sarcoplasmic reticulum. Better-regulated calcium cycling could support both contraction and relaxation of the heart muscle.

The goal is therefore not to replace the heart with new muscle cells, but to modify signaling inside existing cardiomyocytes. Whether that mechanism translates into better clinical outcomes is the question GenePHIT is designed to answer.

How the Phase 2 study builds on Phase 1

GenePHIT follows a first-in-human Phase 1 study whose 12-month findings were published in Nature Medicine in 2025. That earlier study provided preliminary information about the feasibility of delivering AB-1002 through the coronary arteries and offered early safety and activity signals. 6

However, the Phase 1 study was small, non-randomized, and not designed to establish clinical efficacy. A randomized, placebo-controlled Phase 2 trial is a substantially stronger test because it can compare outcomes between participants receiving AB-1002 and those receiving placebo while limiting the influence of expectation, disease variation, and other confounding factors. 6

Regulatory designations are not approval

AskBio has reported FDA Fast Track and Orphan Drug designations for AB-1002, along with EMA PRIME designation or eligibility. These programs can support and potentially accelerate development of medicines addressing serious diseases or unmet medical needs, but they do not establish that AB-1002 is safe or effective and do not represent marketing authorization. 5

AB-1002 remains investigational while GenePHIT outcomes are pending.

Why the study matters—and what it does not show yet

Heart failure affects an estimated 64 million people worldwide, and some patients remain symptomatic or continue to deteriorate despite medicines and devices. A successful one-time gene therapy could eventually complement chronic treatment with a disease-mechanism-directed approach. 12

But the ESC 2026 presentation should be read as a trial-progress update, not as evidence that the therapy improves survival, symptoms, ejection fraction, exercise capacity, or quality of life. The reported data described enrollment and baseline characteristics; the controlled comparison with placebo remains the decisive next step. Initial efficacy and safety results are expected in the first half of 2027. 125